Novo Nordisk oral Wegovy enters Brazil, Goldman flags Hypera risk

Novo Nordisk's oral formulation of Wegovy is launching in Brazil, expanding the addressable patient pool beyond injectable GLP-1s. Goldman Sachs warns this intensifies competitive pressure on local pharma Hypera, which has a stake in the obesity market. The move signals a shift in Brazil's weight-loss drug landscape, with potential market-share implications for domestic players.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works